Last reviewed · How we verify
Recombinant Von Willebrand factor
Recombinant von Willebrand factor replaces or supplements the natural von Willebrand factor protein to restore platelet adhesion and coagulation factor VIII binding.
Recombinant von Willebrand factor replaces or supplements the natural von Willebrand factor protein to restore platelet adhesion and coagulation factor VIII binding. Used for Von Willebrand disease (Type 1, 2, and 3), Factor VIII deficiency associated with von Willebrand disease.
At a glance
| Generic name | Recombinant Von Willebrand factor |
|---|---|
| Also known as | rVWF, Vonvendi, vonicog alfa, Vonvendi |
| Sponsor | Nicoletta C Machin |
| Drug class | Recombinant coagulation factor |
| Target | Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Von Willebrand factor (vWF) is a critical blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for coagulation factor VIII. The recombinant form is produced through genetic engineering and functions identically to endogenous vWF, restoring hemostatic function in patients with von Willebrand disease or factor VIII deficiency by enabling proper platelet plug formation and stabilizing factor VIII levels.
Approved indications
- Von Willebrand disease (Type 1, 2, and 3)
- Factor VIII deficiency associated with von Willebrand disease
Common side effects
- Thrombosis
- Allergic reaction
- Injection site reactions
- Headache
- Fever
Key clinical trials
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)
- An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A (PHASE1)
- Recombinant vWF Concentrate and ECMO (PHASE1)
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa (PHASE3)
- A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) (PHASE3)
- Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Von Willebrand factor CI brief — competitive landscape report
- Recombinant Von Willebrand factor updates RSS · CI watch RSS
- Nicoletta C Machin portfolio CI